←
DevermanLab69 posts
DevermanLab avatar

DevermanLab

@DevermanLab

Engineering viral vectors for gene therapy @stanleycenter @broadinstitute

◷ Joined February 2019▧ 5 Photos and videos
DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

We believe this strategy will accelerate the development of AAV gene delivery vectors that bind defined targets on different disease-relevant cell types with high specificity and across species to enable translation from preclinical models to investigational human gene therapies.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

Our approach derives novel AAV capsid-receptor interactions via peptide modification of capsids, and can be expanded to (1) target more proteins as advances are made in cell type characterization & (2) take advantage of increasingly sophisticated computational approaches.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

In addition, a single round of screening generated reproducible and quantitative data, which allowed us to use saturation mutagenesis and machine learning to nominate additional, novel candidates that were successfully validated in subsequent screening.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

As anticipated, the enhanced tropisms of these capsids depend on the expression of the target protein in the host. LY6A-binding capsids from our study exhibit enhanced BBB-crossing in C57BL/6J but not BALB/cJ mice; LY6C1-binders work well in both.

Post attachment
DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

As a proof-of-concept, we screened for peptide-modified AAV9 capsids that bind in vitro to LY6A or LY6C1, two cell proteins expressed on the mouse blood-brain barrier. Hundreds of these capsids were found to cross the mouse blood-brain barrier better than AAV9.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

We present a mechanism-focused approach where capsids are first screened for a mechanism of action (e.g., binding to a specific protein) and then validated for function. One round of screening in vitro identified 100s of capsids confirmed to exhibit enhanced CNS tropisms in vivo

Post attachment
DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

Conventional selections can identify capsids with the function of interest (e.g., crossing blood-brain barrier) but do not discriminate by mechanism of action. As a result, these capsids may not utilize mechanisms conserved across species & may not translate to clinic.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

Our study is important because gene therapy with recombinant AAVs can treat diseases at their root cause, but is constrained by inefficient gene delivery. AAVs can be engineered to dramatically improve their ability to target cells of interest.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

In addition, this approach generates data suitable for training generative #MachineLearning models to find more AAV capsids that bind to specific target proteins. It presents a new avenue for building substantially more performant ML models in the field of vector engineering.

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

This work shows 1. AAVs can be engineered to specifically engage new proteins 2. This can reduce the use of animals for multi-round selections 3. Nearly all published AAV capsids engineered to cross the BBB via selections in mice use LY6A or LY6C1 (not present in primates).

DevermanLab avatar
DevermanLab@DevermanLab·14 Nov 2022

We have released a preprint “Targeting AAV vectors to the CNS via de novo engineered capsid-receptor interactions”. We developed gene delivery vectors with known mechanisms of action & predictable tropisms by targeting AAVs to specific proteins. tinyurl.com/2ndsuvp6